Thursday, June 26, 2025

Viz.ai & Guardant Health Partner to Enhance Lung Cancer Care

Related stories

Gurobi Unveils Gurobot an AI Assistant for Instant Support

Gurobi Optimization has introduced a new AI Assistant designed...

Deloitte Unveils AI tools to boost human-machine workforce

Designed to identify AI impacts on tasks and skills,...

EPAM unveil DIAL 3.0, evolved genAI platform for enterprise

EPAM Systems, a global digital engineering powerhouse, unveiled DIAL 3.0,...

HPE Launches NVIDIA AI Factory Solutions for Global Adoption

HPE and NVIDIA launch AI factory solutions to boost...

Kognitos Launches Neurosymbolic AI with $25M Series B

Kognitos, a leader in AI automation for business operations,...
spot_imgspot_img

Proposed collaboration aims to integrate cutting-edge AI and genomic insights to advance guideline-directed medical therapy

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced a proposed collaboration with Guardant Health, Inc., a leading precision oncology company, to address challenges in lung cancer care. The collaboration aims to help oncologists diagnose lung cancer earlier and make more informed treatment decisions to improve patient outcomes, reflecting the companies’ shared commitment to leveraging technology to close critical gaps in cancer care and streamline the patient journey.

“This collaboration represents a promising step forward in the fight against lung cancer and reflects our commitment to expanding Viz.ai’s impact in oncology,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “Together, we have the opportunity to harness the power of AI and genomics to ensure patients receive timely, personalized, and effective care.”

Also Read: Atropos Health Boosts Precision Medicine with AI Models

Nearly 40% of lung cancer patients are estimated not to be receiving guideline-directed medical therapy.1 Delays in diagnosis, testing, and appropriate treatment increase the risk of lung cancer progression to advanced-stage disease and can contribute to higher mortality rates. The intent of the proposed collaboration between Viz.ai and Guardant is to address clinical practice gaps along the lung cancer patient journey by facilitating timely biomarker testing with the Guardant360® CDx liquid biopsy, thereby accelerating time to precision diagnosis and optimal treatment selection.

The Viz.ai One platform leverages machine learning algorithms to analyze data from imaging, the EHR and other tests and deliver real-time, actionable insights and automated assessments to accelerate diagnosis and treatment. Viz.ai acts as a safety net in 1,700 hospitals to automatically identify patients with disease and direct them to the right specialist and the right treatment.

Source: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img